InsiderStreet Equity Research

Produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation for any investor. Do not rely on it for any investment decision.

Last Close

$187.31

2026-10-16

Market Cap

$12.0B

Volume

0.5M

52-Wk High

$247.49

52-Wk Low

$101.00

Trailing PE

16.1

P/S

0.85

Gross Margin

31.0%

Net Margin

6.0%

ROE

-124%

ROIC

11%

Piotroski

7/9

Altman Z

1.7

1-Yr Return

+49.5%

5-Yr Return

+235.0%

DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.

SectorHealthcareIndustryMedical - Care FacilitiesExchangeNYSEMarket Cap$12.0BEmployees78,000 (SEC-filed)CEOJavier J. RodriguezIPO1995-10-31CountryUS

2000 16th Street, Denver, CO 80202 · Tel 720 631 2100 · davita.com

INSIDERSTREET SCORE44 / 100Street mean $228.80 (5 analysts, last qtr) — their number, not ours

INSIDER CONSENSUS SIGNALROUTINE SELLING — LOW SIGNAL$254M sold / 6 mo, zero open-market buys

1 Year vs S&P 500 · DVA +49.5% · S&P 500 +15.9% · spread +33.7pp

7 Years vs S&P 500 · DVA +235.0% · S&P 500 +189.9% · spread +45.2pp

Both charts indexed to 100 at the start of their window and drawn on a single shared scale, so the gap to the benchmark is the gap you see. Adjusted closes throughout.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

INSIDERSTREET
SCORE44of 100

Score Breakdown

Profitability	30/100
Growth	56/100
Momentum	75/100
Quality	64/100
Earnings Quality	63/100
Balance Sheet	27/100
Value	51/100
Risk (safety)	30/100
Overall	44.4/100

Each component is a diagnostic reading on its own 0-100 scale. The overall score is computed separately from the underlying financials and is not the average of the rows above — components are not equally weighted and three of them (Momentum, Value, Risk) are derived partly from price rather than from the business.

Peer Comparison — IS Score

Symbol	IS Score
EHC	64
UHS	61
ENSG	65
PACS	56
CHE	61
THC	63
DVA	44

IS Score Trend — quarterly

14 quarters, 23 Q1 to 26 Q2. Peak 51 in 25 Q1, latest 44 — -6 since. Fell in 2 of the last 4 quarters. Dashed line marks 40 on the 0-100 scale.

BUSINESS QUALITY44 / 100IS Score 44.4 / 100 · -6.1 from peak of 51

Fundamental factor model, quarterly. Measures how the business is doing - not where the price is going.

PRICE STRUCTUREBULLISHTechnical Score 81 / 100 · Power +62 · 19 of 22 indicator votes bullish

Vote share across trend, momentum, volume, volatility and pattern families. Describes where the price is, not where it is going.

These two disagree — business quality 44, price structure 81 out of 100, so the price reads better than the business does. We publish the disagreement rather than resolving it: they answer different questions, and the gap between them is information, not an error.

Trigger	Where it stands now	What it would mean
IS Score reaches 55 and holds two consecutive quarters	now 44.4	would move us up one band
IS Score stops falling - one quarter higher than the prior	last four: 38 → 35 → 38 → 44	the direction matters more than the level
Technical vote share back above 50%	now 91%	price structure no longer broken
Institutional holder count rises two quarters running	peak 630 → now 630	fewer institutions willing to hold is our clearest warning

We publish these so the view can be shown to be wrong. If none of them move and our reading does, we owe you an explanation.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

This page is InsiderStreet's own reading, produced from the data in the rest of this document. It is not a price target and not investment advice. Analyst consensus and street price targets appear later under their own heading and are the street's numbers, not ours.

Site Convergence Score2 of 4top 13% of 29,420 symbols

Sources Aligned— of 3independent disclosures

Congress (180d)1 buys2026-03-27

Insider Buys (180d)0none disclosed

ETF Funds (30d)540 up / 392 downnet +148 funds

Congressional and insider figures are disclosed purchases in the trailing 180 days; ETF figures are COUNTS OF FUNDS whose holding changed in 30 days, not dollars. Coincidence of separate disclosures, not coordination. An absent source means nothing qualifying was disclosed in its window.

Institutions holding — 12 quarters

Peak 630 · latest 630 (+0 from peak).

Quarter	Holders	13F shares	Value	Reported own%	Guard
2026 Q2	630	59.4M	$12.9B	91.7%
2026 Q1	581	62.1M	$9.5B	95.8%
2025 Q4	532	66.5M	$7.5B	102.6%	ex-outlier 53.6%
2025 Q3	562	67.3M	$8.9B	103.8%	ex-outlier 54.2%
2025 Q2	590	70.4M	$10.0B	108.7%
2025 Q1	594	71.2M	$10.9B	110.0%
2024 Q4	597	73.6M	$11.0B	113.7%
2024 Q3	597	74.5M	$12.1B	115.1%
2024 Q2	556	76.2M	$10.4B	117.6%
2024 Q1	539	77.8M	$10.6B	120.1%
2023 Q4	532	79.0M	$8.2B	122.0%
2023 Q3	498	79.2M	$7.4B	122.3%

How to read ownership above 100%. A 13F reports the positions a manager has investment discretion over, and where two or more managers share discretion over the same block, each one reports it. Summed across filers, the total can therefore exceed the shares actually outstanding without anything being wrong. We publish the figure as filed rather than netting it down, and flag separately any quarter where the arithmetic is not merely high but impossible.

Why 2025-12 reads 102.61%. Institutions cannot hold more of a company than exists. The reported 66.5M shares exceed the 64.8M outstanding, and a single filer accounts for the excess: Berkshire Hathaway Inc reports 31,759,065 shares, which alone would be 49.0% of the company. Excluding that filing, ownership is 53.6%. We publish both figures. 13F filings are due 45 days after quarter end and amendments keep arriving after that, so the newest quarter is provisional by construction - this is what an unsettled quarter looks like.

Why 2025-09 reads 103.85%. Institutions cannot hold more of a company than exists. The reported 67.3M shares exceed the 64.8M outstanding, and a single filer accounts for the excess: BERKSHIRE HATHAWAY INC reports 32,160,579 shares against 33,796,541 the prior quarter, a 1x jump, which alone would be 49.6% of the company. Excluding that filing, ownership is 54.2%. We publish both figures. 13F filings are due 45 days after quarter end and amendments keep arriving after that, so the newest quarter is provisional by construction - this is what an unsettled quarter looks like.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Insider	Role	Date	Type	Shares	Value	Post-Txn Owned
Maughan David Paul	Chief Operating Officer, DKC	2026-09-22	TAX W/H	7,501	$1.37M	86,604
Hollar Jason M.	director	2026-08-15	A-Award	278	—	6,883
Desoer Barbara J	director	2026-08-15	A-Award	278	—	278
Schechter Adam H	director	2026-08-15	A-Award	278	—	5,970
Moore Gregory J.	director	2026-08-15	A-Award	278	—	8,091
Pullin Dennis W	director	2026-08-15	A-Award	278	—	2,949
Schoppert Wendy Lee	director	2026-08-15	A-Award	278	—	278
Arway Pamela M	director	2026-08-15	A-Award	278	—	27,223

6-mo decomposition (Form 4)	Txns	Shares	Value	Signal weight
S — Open-market sales	11	1,577,352	$254.4M	Counted
M — Exercises (paired A/D)	1	5,784	$0.6M	None — mechanics
F — Tax withholding	15	109,986	$16.9M	None — compensation
G — Gifts	1	5,038	—	None
P — Open-market purchases	0	0	$0	Counted — none occurred

Monthly Net Insider Flow (000 shares)

Net of acquisitions minus dispositions, all Form 4 types.

Signal Summary

SignalRoutine Selling — Low Signal

Open-Market Sells$254.4M11 txns / 6 mo

Open-Market Buys$0.0M0 txns / 6 mo

ClusterNone active3+ insiders / 21 days

Filed	Filer	Shares registered	Est. proceeds
2026-06-16	Javier Rodgriguez	39,407	$8.2M
2026-06-15	Waters Kathleen Alyce	6,455	$1.3M
2026-06-15	Kathleen Waters	8,950	$1.9M
2026-06-15	Javier Rodriguez	30,000	$6.3M
Trailing 12 mo	8 filings	173,996	$35M

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Filed	Form	Reporting person	% of class	Shares
2025-10-30	SCHEDULE 13G/A	The Vanguard Group	5.91%	4.2M sh
2025-04-25	SCHEDULE 13G/A	BlackRock, Inc.	5.00%	4.0M sh
2025-02-13	SCHEDULE 13D/A	Berkshire Hathaway Inc.	45.00%	35.9M sh
2025-02-13	SCHEDULE 13D/A	GEICO Corporation	23.00%	18.3M sh

Member	Chamber	Trade	Size band	Traded	Disclosed
Julie Johnson	House	SELL	$1,001 - $15,000	2025-09-25	2025-10-08
Julie Johnson	House	SELL	$1,001 - $15,000	2025-09-24	2025-10-08
Julie Johnson	House	SELL	$1,001 - $15,000	2025-09-23	2026-08-06
Alan Armstrong	Senate	BUY	$1,001 - $15,000	2026-03-27	2026-07-20
Jerry Moran	Senate	SELL	$1,001 - $15,000	2023-12-14	2024-01-17
Jerry Moran	Senate	SELL	$1,001 - $15,000	2023-12-14	2024-01-17

House 12-Mo9 trades3 purchases

Senate 12-Mo1 trades1 purchases

CoverageSTOCK Act filings30-45 day disclosure lag

13F Filers (last complete Q)581

13F Shares62M95.8% of shares out

New / Closed130 / 69positions, QoQ

Increased / Reduced166 / 212positions, QoQ

Put/Call (13F)0.94option positions

Free Float97.9%62M sh

2.8 · Largest Reporting 13F Managers

Manager	Shares	Value
Wedge Capital Management L L P/Nc	189,480	$33M
Counterpoint Mutual Funds Llc	51,875	$9M
Ghp Investment Advisors, Inc.	39,053	$7M
Stolper Co	35,038	$6M
Assenagon Asset Management S.A.	20,602	$4M
Curated Wealth Partners Llc	19,883	$3M

EDGAR 13F holdings as of 2026-09-30; filer values normalized to dollars.

2.9 · Top ETF & Fund Ownership

Fund	Weight	Position
RSP	0.2%	$195M
VITSX	0.0%	$195M
VSMPX	0.0%	$195M
VTSAX	0.0%	$195M
VTI	0.0%	$195M
VFIAX	0.0%	$155M

13F Filers Holding DVA — quarterly

Institutional Put/Call — quarterly

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Daily short-sale volume as % of volume reported in FINRA's short-sale file — a flow measure, not short interest; dashed = 50-day average.

Latest Session62.3%2026-10-15

20-Day Avg71.8%50-day 73.2%

TrendFalling20d vs 50d

By Market CenterQ: 62% · N: 70% · B: 71%latest session

Weekly Notional ($B)

Where DVA Trades in the Dark

ATS Venue (4-wk)	Shares	Avg trade
Ubsa Ubs Ats	1.4M	47 sh
Incr Intelligent Cross Llc	1.3M	35 sh
Sgmt Sigma X2	1.1M	35 sh
Mstx Ms Trajectory Cross (Ats-1)	1.0M	29 sh
Mlix Instinct X	0.9M	52 sh
Mspl Ms Pool (Ats-4)	0.7M	147 sh

Where a dollar of DaVita Inc. revenue goes. All values FY2025 filings, live.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

DVA (live moat model)Peer median: EHC · UHS · ENSG · PACS · CHE

Component scores from the live moat model. Peer median illustrative.

Moat score 46/100 — Weak; primary source Cost Advantage.

3.8 · Employees (SEC filings)

Officer	Title
Javier J. Rodriguez	Chief Executive Officer & Executive Director
David Maughan	Chief Operating Officer of DaVita Kidney Care
Joel Ackerman	Chief Financial Officer & Treasurer
Kathleen Alyce Waters	Chief Legal & Public Affairs Officer

Revenue ($B)

EPS ($) — GAAP diluted actual, street-basis estimate

Actual bars are GAAP diluted EPS from the filed income statement; the lighter forward bars are street-basis consensus. The two are different measures and are not comparable quarter to quarter.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Quarterly EPS — Actual vs. Consensus

Beats (>2%)5 of 6recent quarters

Avg Surprise+3.1%

Next Report2026-10-28

Income Quality1.74OCF ÷ net income

Beat Rate—%0 of 0 quarters

Current Streak0longest 0

Avg EPS Surprise—%median —%

Surprise Trend—last 4 vs prior 4

Period	EPS est.	EPS actual	EPS surprise	Rev est. ($M)	Rev actual ($M)	Rev surprise

Announcement dates to . Consensus as it stood at each report. Revenue surprise shown where both estimate and actual are filed. A beat record is history, not a forecast.

Profit Margins (%)

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Revenue by Segment — Stacked

Live segmentation data.

YoY Growth Heatmap — Income Lines

YoY growth	FY21	FY22	FY23	FY24	FY25
Revenue	+0.6%	-0.1%	+4.6%	+5.6%	+6.5%
Gross profit	+2.4%	-6.7%	+12.4%	+10.4%	-12.6%
Operating income	+6.1%	-25.5%	+19.7%	+30.4%	-3.8%
Net income	+26.5%	-42.7%	+23.4%	+35.4%	-20.2%

$B · FY ends	FY21	FY22	FY23	FY24	FY25
Revenue	11.6	11.6	12.1	12.8	13.6
Cost of revenue	8.0	8.2	8.3	8.6	10.0
Gross profit	3.6	3.4	3.8	4.2	3.7
R&D expense	0.0	0.0	0.0	0.0	0.0
SG&A expense	1.2	1.4	1.5	1.5	1.7
Operating income	1.8	1.3	1.6	2.1	2.0
EBITDA	2.5	2.1	2.3	2.7	2.6
D&A	0.7	0.7	0.7	0.7	0.7
Pretax income	1.5	1.0	1.2	1.5	1.3
Income tax	0.3	0.2	0.2	0.3	0.3
Net income	1.0	0.6	0.7	0.9	0.7
Diluted EPS ($)	8.90	5.85	7.42	10.73	9.51
Diluted shares (M)	110	96	93	87	88

Operating CF$2B

CapEx$1B

Free cash flow$1B

SBC$0B

Buybacks$2B

Net cash change$-0B

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet — Full

$B	FY22	FY23	FY24	FY25
Cash & equivalents	0.2	0.4	0.8	0.8
ST investments	0.1	0.0	0.1	0.0
Receivables (net)	2.3	2.2	2.6	3.0
Total current assets	3.2	3.1	3.7	4.1
PP&E (net)	5.9	5.6	5.3	5.2
Goodwill + intangibles	7.3	7.3	7.6	7.8
Total assets	16.9	16.9	17.3	17.5
Accounts payable	0.5	0.5	0.5	0.7
Short-term debt	0.2	0.1	0.3	0.1
Deferred revenue	0.0	0.0	0.0	0.0
Total current liabilities	2.6	2.6	3.0	3.1
Long-term debt	8.7	8.3	9.2	12.3
Total liabilities	14.7	14.2	15.2	16.3
Shareholders' equity	2.2	2.7	2.1	1.2

Cash Flow Statement — Full

$B	FY22	FY23	FY24	FY25
Net income	0.8	0.7	1.3	1.1
D&A	0.7	0.7	0.7	0.7
Stock-based compensation	0.1	0.1	0.1	0.1
Working capital change	0.0	0.2	(0.0)	(0.3)
Operating cash flow	1.6	2.1	2.0	1.9
Capital expenditures	(0.6)	(0.6)	(0.6)	(0.6)
Investing cash flow	(0.6)	(0.8)	(0.8)	(0.7)
Buybacks	(0.8)	(0.3)	(1.4)	(1.8)
Dividends paid	0.0	0.0	0.0	0.0
Debt issuance / (repay)	(0.0)	(0.6)	1.1	0.8
Financing cash flow	(1.1)	(1.2)	(0.8)	(1.4)
Free cash flow	1.0	1.5	1.5	1.3

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Balance Sheet Structure ($B)

Cash Generation vs Capex ($B)

Left: what the balance sheet is made of — the gap between the assets bar and the liabilities bar is book equity. Right: whether the capex bar is covered by the operating-cash bar; where it is not, the difference was funded externally and free cash flow goes negative.

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
PROFITABILITY
ROE	91.5%	76.4%	78.2%	159.1%	-281.8%	-124%
ROA	5.7%	3.3%	4.1%	5.5%	4.3%	4.8%
ROIC	11.7%	8.7%	11.1%	15.1%	11.7%	11.2%
Gross margin	31.4%	29.3%	31.5%	32.9%	27.0%	31.0%
Operating margin	15.5%	11.5%	13.2%	16.3%	14.7%	15.1%
Net margin	8.4%	4.8%	5.7%	7.3%	5.5%	6.0%
EBITDA margin	21.4%	17.7%	19.1%	21.3%	19.4%	19.7%
FCF margin	11.1%	8.3%	12.3%	11.4%	9.6%	—
VALUATION
P/E	12.19	12.25	14.06	13.39	13.40	16.1
P/B	15.79	9.63	9.20	103.53	-15.37	-15.9
P/S	1.03	0.59	0.80	0.98	0.73	0.85
P/FCF	9.25	7.14	6.51	8.55	7.64	7.4
EV/EBITDA	9.43	8.93	8.81	8.72	9.19	8.0
EV/Revenue	2.02	1.58	1.68	1.85	1.78	1.6
Earnings yield	8.2%	8.2%	7.1%	7.5%	7.5%	6.98%
FCF yield	10.8%	14.0%	15.4%	11.7%	13.1%	13.47%

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
LEVERAGE & SOLVENCY
Current ratio	1.32	1.20	1.19	1.26	1.29	1.47
Quick ratio	1.28	1.16	1.13	1.21	1.24	1.41
Debt / equity	15.85	16.60	10.53	99.63	-23.12	-14.09
Debt / assets	69.9%	69.8%	65.8%	69.8%	86.1%	60.9%
Net debt / EBITDA	4.63	5.59	4.62	4.12	5.40	3.66
Interest coverage	6.32	3.71	3.95	4.25	3.51	—

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Ratio	FY21	FY22	FY23	FY24	FY25	TTM
EFFICIENCY
Asset turnover	0.68	0.68	0.72	0.75	0.78	0.79
Receivables turnover	6.14	5.51	5.42	5.87	5.98	4.6
DSO (days)	59	66	67	62	61	79
DPO (days)	19	20	22	23	24	27
Cash conversion cycle	45	51	51	46	43	58
GROWTH (YoY)
Revenue growth	0.6%	-0.1%	4.6%	5.6%	6.5%	—
Net income growth	26.5%	-42.7%	23.4%	35.4%	-20.2%	—
EPS growth	39.9%	-34.7%	22.2%	49.8%	-24.1%	—
FCF growth	-1.2%	-25.5%	55.3%	-1.7%	-10.6%	—
PER SHARE ($)
EPS (diluted, TTM)	9.33	6.10	7.45	11.17	8.48	13.08
Book value / share	7.21	7.75	11.38	1.44	-7.39	16.66
Revenue / share	110.82	126.32	130.85	152.83	154.86	216.26
FCF / share	12.30	10.46	16.09	17.49	14.88	24.85
Cash / share	4.62	3.50	4.22	10.09	8.88	10.63
SHAREHOLDER RETURN & SCORES
Buyback yield	13.4%	12.2%	3.3%	11.9%	17.9%	10.61%
Altman Z-Score	1.59	1.28	1.52	1.80	1.55	1.7
Piotroski F-Score	8	6	7	8	5	7/9
Beneish M-Score	-2.69	-2.61	-2.91	-2.65	-2.58	-2.81

Model	Score	Zone	Note
Piotroski F-Score	7 / 9	Strong
Altman Z-Score	1.7	Distress (<1.81)	Distress
Income quality	1.74	Cash-backed	OCF ÷ net income
Beneish M-Score	-2.81	Non-manipulator	vs −2.22 threshold

DuPont Decomposition (TTM)	Value
Tax burden	0.58
Interest burden	0.71
Operating margin	14.7%
Asset turnover	0.80×
Financial leverage	-31.02×
= ROE	-149%

Growth Quality (live)	Value
Revenue stability	0.88
Earnings stability	0.01
Earnings persistence	0.99
Revenue CAGR 3y	6.1%
EPS CAGR 3y	36.8%
FCF CAGR 3y	5.9%

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Buyback Yield10.61%

Dividend Yield0.00%none paid

Total Shareholder Return11.40%cash yield

SBC / Revenue0.9%dilution pressure

Company	Mkt cap	P/E	ROE	Net margin	Rev growth	Piotroski	1-yr ret
EHC	$12.6B	20.6	25%	9.6%	+9.5%	9/9	+4.0%
UHS	$10.9B	7.5	21%	7.7%	+10.0%	8/9	-9.3%
ENSG	$10.3B	26.9	17%	6.9%	+18.9%	7/9	-1.6%
PACS	$7.4B	27.6	28%	5.3%	+15.2%	8/9	+276.9%
CHE	$6.7B	25.7	27%	10.1%	+3.3%	6/9	—
THC	$21.5B	10.2	53%	14.7%	+5.4%	7/9	—
HIMS	$6.3B	-46.0	-32%	-11.5%	+28.0%	4/9	—
CON	$4.9B	24.9	48%	10.8%	+14.0%	9/9	—

1-yr returns computed from adjusted price history; peers without a tracked series show —.

Hold

23 Analysts

Str Sell (0)Sell (1)Hold (12)Buy (10)Str Buy (0)

Mean Target (qtr)$228.805 targets

Target vs. Price+22.2%last-quarter mean

Next Report2026-10-28street $3.57

Consensus estimates	Revenue mean	High / Low	EPS mean	High / Low	# EPS est.
FY2026	$14.10B	$14.32B / $13.96B	$14.83	$15.80 / $13.54	5
FY2027	$14.53B	$15.00B / $14.30B	$16.96	$17.10 / $16.73	5
FY2028	$15.00B	$15.86B / $14.29B	$19.54	$20.71 / $18.92	3

Street Price Target — Trajectory

Window	Avg Target	vs. Price	# Targets
Last Quarter	$228.80	+22.2%	5
Last Year	$210.00	+12.1%	15
All Time	$181.42	-3.1%	24

Rolling mean of published targets vs. last close $187.31. Aggregated from StreetInsider, Benzinga, Pulse 2.0.

Third-Party Composite Rating

B-

DCF

5/5

ROE

1/5

ROA

4/5

Debt/Eq

1/5

P/E

3/5

P/B

1/5

Independent quant composite as of 2026-10-16; components scored 1–5 (5 best). Shown for contrast with the InsiderStreet Score — methodologies differ.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

DVA +49.5% vs S&P 500 +15.9% — spread +33.7pp

Sector — XLV +24.2%

Peer Set — indexed to 100

All series indexed to 100 at the start of the window, adjusted closes.

Candlesticks with SMA 20/50 overlay, Bollinger (20,2σ) band, volume, and Wilder RSI(14) — computed from live daily OHLCV.

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Moving Average	Value	Distance	% Distance	Signal
SMA 20	$179.94	+7.37	+4.10%	Above
SMA 50	$180.49	+6.82	+3.78%	Above
SMA 200	$173.37	+13.94	+8.04%	Above
EMA 9	$182.84	+4.47	+2.44%	Above
EMA 21	$181.69	+5.62	+3.09%	Above
EMA 50	$185.59	+1.72	+0.93%	Above
EMA 200	$177.11	+10.20	+5.76%	Above

Series and readings from the nightly technical-indicator history — identical data to the site's ribbon chart. Supertrend segments colored by direction.

TECHNICAL VERDICTBULLISHPower Score +6219 of 22 indicator votes bullish

Family Scores (site weights)

Trend 30%89

Momentum 25%91

Volume 20%69

Volatility 10%100

Patterns 15%50

This Week91% bullishof 11 price-based votes

4 Weeks Ago64%+27 pts since

12 Weeks Ago82%+9 pts since

ReadImprovingweek-over-week trajectory

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Price vs SMA 20$179.94

Price vs SMA 50$180.49

Price vs SMA 200$173.37

EMA 9/21 Cross182.8/181.7

SMA 50/200Golden

ADX DirectionADX 15

Supertrend$191

Parabolic SAR$175

SMA Slope0.170

RSI57.6

Stochastic K/D83/79

StochRSI K/D89/92

Williams %R-16

CCI174

TSI vs Signal0.2

CMO15.3

ROC4.82%

OBV SignalAccum

Chaikin MF-0.240

MFI69

Force Index0M

Elder Ray Bull8.22

RSI (14)30 oversold · 70 overbought

Stochastic %Kvs %D 79

Money Flowvolume-weighted RSI

ADXtrend strength · <20 weak

Williams %Rinverted scale

Level	Value	Level	Value
Pivot / R1 / R2	$186.94 / $191.47 / $193.78	S1 / S2	$184.63 / $180.10
Bollinger (20,2)	$172.26 – $187.61	Squeeze	Off
52-wk range	$101.00 – $247.49	Off 52-wk high	-24.3%
ATR (14)	$4.67 (2.5%)	Historical vol	29.2%

+2.2%Jan55%

+1.5%Feb50%

+0.8%Mar48%

+1.5%Apr55%

-1.4%May50%

+1.5%Jun50%

-0.3%Jul50%

+0.6%Aug50%

+0.2%Sep50%

-2.1%Oct50%

+4.8%Nov60%

+0.7%Dec50%

Sample: 20 years — treat short histories as suggestive, not statistical.

Computed from live weekly prices	DVA	S&P 500
Weekly volatility (σ, 1y)	7.96%	1.83%
Best / worst week (1y)	+34.2% / -21.7%	—
Max drawdown (5y, monthly)	-47.3%	—
1-week VaR (95%)	-7.9%	—
Beta (5y)	0.83	1.00

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

DVA EQUITY WEATHER (LIVE)CLOUDY · +0

Trend-5

Momentum+40

Volume+19

Volatility-60

Breadth-30

MARKET REGIME (2026-10-16)NEUTRAL

VIX19.99Normal

Dow TheoryConfirmed Bearish

SPY / QQQ TSI7.2 / 4.7trend strength

Sector Strength46/100breadth average

Average sentiment of 225 stories, weekly buckets, −1 to +1.

Overall+0.3+23.5 vs industry

Trend-4.9+21.1 vs industry

Momentum+40.0+60.1 vs industry

Volume+19.0+44.0 vs industry

Reading	DVA	Medical - Care Facilities n=442	Healthcare n=5,272	All US symbols n=70,435
Overall	+0.3	-23.2	-24.0	-20.5
Trend	-4.9	-26.0	-25.6	-21.3
Momentum	+40.0	-20.1	-28.5	-15.8
Volume	+19.0	-25.0	-25.0	-3.8

Trend, momentum and volume are computed per company. Volatility and breadth are market-regime values shared by every symbol in the universe, so they are reported once under Market Regime rather than compared here - a company cannot differ from its sector on a constant.

Executive	Total comp	Structure
Javier J. Rodriguez Chief Executive Officer	$18.2M	74% equity+incentive
Joel Ackerman Chief Financial Officer and Tr	$6.1M	72% equity+incentive
David P. Maughan Chief Operating Officer, Da	$5.6M	69% equity+incentive
Kathleen A. Waters Chief Legal and Public Af	$3.9M	68% equity+incentive
James O. Hearty Chief Compliance Officer	$2.0M	60% equity+incentive

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Pillar (live disclosure scores)	Score
Environmental	64
Social	52
Governance	63
Composite ESG	59

Composite ESG Trend

Filed	8-K contents	Items
2026-08-04	Earnings Release; Exhibits	2.02,9.01
2026-06-08	Material Agreement; Financial Obligation; Shareholder Vote; Exhibits	1.01,2.03,5.07,9.01
2026-05-05	Earnings Release; Exhibits	2.02,9.01
2026-02-02	Results of Operations and Financial Condition; Financial Statements an	2.02,9.01
2025-11-25	Entry into Material Definitive Agreement; Creation of Direct Financial	1.01,2.03,9.01
2025-10-29	Results of Operations and Financial Condition; Financial Statements an	2.02,9.01
2025-08-20	Other Events	8.01
2025-08-05	Results of Operations and Financial Condition; Financial Statements an	2.02,9.01

Methodology. Every figure originates in InsiderStreet's production data layer and is computed deterministically by the same engines that power insiderstreet.ai. This factsheet contains no model-written text. Sections without underlying data are omitted rather than estimated.

DISCLOSURES. This document is produced by InsiderStreet.ai from live production data. It is not investment advice, not an offer or solicitation to buy or sell any security, and not a recommendation tailored to any person. Data is sourced as of the dates shown and may no longer be current. InsiderStreet.ai is not a registered investment adviser or broker-dealer. Investing involves risk, including loss of principal. Past performance does not guarantee future results. Do not make any investment decision based on this document. © 2026 InsiderStreet.ai — all rights reserved. Redistribution prohibited.

This space intentionally left blank — the next section begins on the following page

NOT INVESTMENT ADVICE — FOR INFORMATIONAL PURPOSES ONLY

Data domain	Source	Coverage for this report
Price & volume	market_db.historical_prices	52 rows
Fundamentals	income_statements_annual	6 rows · 2020 to 2025
Reported vs consensus	fact/earnings_calendar	24 rows · 2020-10-29 to 2026-08-04
Analyst estimates	dim/forward_estimates	3 rows · 2026-12-31 to 2028-12-31
Institutional ownership (13F)	holdings_db.institutional_ownership_summary	104 rows · 2000 to 2026
Insider transactions (Form 4)	edgar/form4	12 rows · 2026-06-15 to 2026-09-22
Proposed sales (Form 144)	edgar/form144	1 record
Beneficial ownership (13D/G)	edgar/13dg	4 rows · 2025-02-13 to 2025-10-30
Short-sale volume (FINRA)	edgar/short_volume_daily	60 rows · 2026-07-23 to 2026-10-15
Dark pool (ATS, tier 1)	edgar/darkpool_weekly	12 rows · 2026-06-15 to 2026-08-31
ETF & fund holding	etf_holdings_changelog (30d)	1 record
Peer set	stock_peers_dynamic	8 rows
Industry medians	industry_medians	1 record
Congressional trades	congress_db (House + Senate)	1 record
ESG	fact/esg_disclosures	1 record

Method. Every figure in this factsheet is looked up from a named field computed in code. It contains no model-written text.

Not covered. Short interest as a percent of float and days-to-cover are not in this data set — the short-sale figures above are FINRA volume, a flow, and cannot support squeeze or covering analysis. Options positioning and intraday data are also absent. 13F ownership is filed 45 days after quarter end and congressional trades are disclosed on a lag, so both describe a past position, not a current one.

DaVita Inc. (DVA)

DaVita Inc. (DVA)

Score Breakdown

Peer Comparison — IS Score

IS Score Trend — quarterly

DaVita Inc. (DVA)

Institutions holding — 12 quarters

DaVita Inc. (DVA)

Monthly Net Insider Flow (000 shares)

Signal Summary

DaVita Inc. (DVA)

2.8 · Largest Reporting 13F Managers

2.9 · Top ETF & Fund Ownership

13F Filers Holding DVA — quarterly

Institutional Put/Call — quarterly

DaVita Inc. (DVA)

Where DVA Trades in the Dark

DaVita Inc. (DVA)

3.8 · Employees (SEC filings)

DaVita Inc. (DVA)

DaVita Inc. (DVA)

DaVita Inc. (DVA)

Balance Sheet — Full

Cash Flow Statement — Full

DaVita Inc. (DVA)

DaVita Inc. (DVA)

DaVita Inc. (DVA)

Street Price Target — Trajectory

Third-Party Composite Rating

DaVita Inc. (DVA)

DaVita Inc. (DVA)

Family Scores (site weights)

DaVita Inc. (DVA)

DaVita Inc. (DVA)

DaVita Inc. (DVA)

DaVita Inc. (DVA)